BioSyent Pharma Launches New RepaGyn® Hormone-Free Vaginal Suppositories

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary
BioSyent Pharma Inc. has commenced the Canadian launch of new RepaGyn(R)
Hormone-Free Vaginal Suppositories.


RepaGyn(R) (sodium hyaluronate) is an innovative vaginal suppository recommended
for the healing of the vaginal mucosa and the treatment of vaginal dryness
caused by menopause, stress and chemotherapy. It is also recommended in
situations where tissue repair is required after invasive vaginal surgeries and
biopsy procedures. RepaGyn(R) vaginal suppositories can be used with or without
local hormone therapy.


RepaGyn(R) is formulated with sodium hyaluronate, a naturally occurring
compound, and offers a hormone-free treatment alternative proven to deliver
symptom relief, restoration of pH balance, and tissue repair in one ovule.
RepaGyn(R) has established clinical evidence of both efficacy and symptom relief
and has been recommended by doctors and successfully used by women in several
European countries including Italy, France, Belgium, Switzerland, Denmark and
Poland for over 10 years under the brand names Cicatridine(R), Cicatridina(R),
Cikatridina(R), and Repadina(R).


 "The launch of RepaGyn(R) is an important milestone in the development of the
BioSyent Pharma business," commented Rene Goehrum, CEO of BioSyent. "The product
itself is consistent with our strategy of sourcing unique products that address
unmet medical needs for the Canadian healthcare market, and represents a further
broadening of our portfolio. The patient population that can benefit from
RepaGyn(R) is significant."


RepaGyn(R) is approved by Health Canada and was in-licensed by BioSyent Pharma
for exclusive marketing and distribution in Canada from FARMA-DERMA s.r.l.,
Italy in October of 2013. Shipments to wholesalers and pharmacies will commence
in June 2014.


To learn more about RepaGyn(R), please visit the website www.RepaGyn.ca.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,776,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
[phone]
[e-mail]
www.biosyent.com